This EBMT Autoimmune Disease Working Party study aimed to evaluate the influence of CD34+ positive graft selection (CD34+) on the outcome of systemic sclerosis (SSc) patients after autologous hematopoietic stem cell transplantation (AHSCT). Clinical and laboratory data from 138 SSc patients at diagnosis, before and after AHSCT were retrospectively analyzed. CD34+ selection was performed in 47.1% (n = 65) patients. By multivariate analysis adjusting for all factors differing between the two groups (without or with CD34+), there was no statistically significant difference in terms of overall survival (hazard ratio (HR): 0.98, 95% confidence interval (CI) 0.40-2.39, P = 0.96), PFS (HR: 1.55, 95% CI 0.83-2.88, P = 0.17) and incidence of relapse or progression (HR: 1.70, 95% CI 0.85-3.38, P = 0.13). We demonstrate that CD34+ does not add benefit to the outcome of SSc patient treated with AHSCT. These findings should be further confirmed by prospective randomized trials.
INTRODUCTION
Systemic sclerosis (SSc) is a chronic autoimmune disease (AD) that affects skin and internal organs. 1 Severe progressive cutaneous SSc with visceral involvement has a poor prognosis, with mortality rates that may reach 30% 5 years after diagnosis, despite standard therapies. 2, 3 In the past 20 years, autologous hematopoietic stem cell transplantation (AHSCT) has been shown to be effective to treat severe or rapidly progressive SSc. Improved skin score and quality of life and at least stabilization of lung function were consistently reported in early phase II trials. [4] [5] [6] [7] [8] Recently, the phase II ASSIST 9 and the larger phase III ASTIS 10 prospective randomized trials showed better survival rates and improved skin, lung and functional status in patients treated with AHSCT as compared with monthly IV cyclophosphamide. Still, the transplant-related mortality reaching 10% and disease-progression rates of around 20-30% after AHSCT indicate that further improvements are still warranted. [6] [7] [8] [9] [10] [11] [12] Among current strategies to increase safety and efficacy of AHSCT, the benefit of ex vivo CD34+ positive selection of the graft remains debated. This study was therefore designed to evaluate the influence of ex vivo CD34+ selection on the outcome of SSc patients treated with AHSCT.
PATIENTS AND METHODS
This Autoimmune Disease Working Party (ADWP) multicenter retrospective study followed the European Society for Blood and Marrow Transplantation (EBMT) guidelines (www.ebmt.org). All EBMT-affiliated centers with eligible SSc patients were invited to participate. The study was approved in each participating center, according to local institutional review board rules, and full informed consent was obtained from all patients before AHSCT. Patients with diagnosis of SSc according to the American College of Rheumatology criteria and having received a first AHSCT between 2000 and 2012 were included, while those having been treated with irradiation as part of the transplant conditioning regimen or enrolled in the former EBMT ASTIS trial 10 were excluded. For centers that agreed to participate, primary data were collected, when available, using a standardized SSc minimal essential data 'B' form. Data were collected by questionnaire or by the electronic EBMT data management system ProMISe. All EBMT participating centers were requested to report all consecutive transplants. Additional clinical and laboratory data at diagnosis, before and after AHSCT were collected. Completed questionnaires were sent by local investigators to the ADWP-EBMT data manager and evaluated for completion and consistency.
Statistics
Study end points were PFS, overall survival (OS), 100-day non-relapse mortality (NRM) and incidence of relapse or progression (RI). Patient-, disease-and transplant-related variables of the CD34+ selected and nonselected groups were compared, using Chi-square or Fisher exact test for categorical variables and Mann-Whitney test for continuous variables. Probabilities of PFS and OS were calculated using the Kaplan-Meier estimate. Cumulative incidence functions were used to estimate relapse and NRM in a competing risk setting. Univariate analyses used log-rank test for OS and PFS; Gray's test for cumulative incidence.
Multivariate analyses were performed using Cox proportional-hazard model. All factors differing between two groups in terms of distribution associated with a non-restrictive P-value o 0.15 were included in the model. All tests were two-sided with type I error rate fixed at 0.05. Statistical analyses were performed with the IBM-SPSS-Statistics, version 22 (IBM, Armonk, NY, USA) and R3.1.2 (R Development Core Team, Vienna, Austria) software packages.
RESULTS AND DISCUSSION
The study enrolled 138 SSc patients from 14 different transplant centers who fulfilled the inclusion criteria. All, but one patient who died shortly after cell infusion, engrafted with median time to absolute neutrophil counts 40.5 × 10 9 /L of 11 days (range: 7-46). The 100-day NRM was 3.6%. The 3-year PFS and OS were respectively 60.2% (95% confidence interval (CI) 51.3-69.2) and 82.7% (75.8-89.6). The 5-year PFS and OS were 60.2% (51.3-69.2) and 81.3% (74.0-88.6) for the whole study group. Ex vivo positive CD34+ selection of the graft (CD34+) had been performed in 47.1% (n = 65) of patients before AHSCT. Baseline characteristics were similar in the CD34+ and non-selected patients, except for the presence of Raynaud's phenomenon before SSc diagnosis and of heart involvement before mobilization, which were more frequent in CD34+ patients ( Table 1) . The CD34+ and non-selected patients were not significantly different for mobilization and conditioning regimens or for interval from mobilization to AHSCT, minimizing although not ruling out any bias imposed by the immunosuppressive regimen. The non-selected patients had all (100%) received serotherapy (antithymocyte globulins (ATG) or alemtuzumab) added to the conditioning regimen as compared with 83% of the CD34+ patients who received serotherapy (ATG) (P = 0.0002). Among all patients treated with ATG (n = 121), 78 (64%) had received the rabbit and 43 (35%) the horse ATG formulation. When the 11 patients not receiving any serotherapy were removed from the analysis, there was no difference in outcomes between the CD34+ selected and non-selected groups.
Of note, when the 127 patients receiving serotherapy were stratified based on the presence of heart involvement before mobilization, outcomes (PFS, OS, NRM and RI) were similar for both the CD34+ selected and non-selected groups ( Table 2 ).
The number of infused CD34+ cells/kg was similar between CD34+ and non-selected patients, indicating that ex vivo selection did not significantly impair cell recovery. By univariate analysis, patient age at diagnosis or at AHSCT, interval from diagnosis or from mobilization to AHSCT, the number of infused CD34+ cells/kg, modified Rodnan's skin score and the presence of Raynaud's phenomenon or lung involvement at diagnosis were not different in terms of OS, PFS, NRM and RI in the CD34+ and non-selected groups. There was also no difference between groups in terms of 100-day NRM (3.1% vs 4.1%; P = 0.75), 3-year OS (80% vs 85%; P = 0.41), PFS (51.2% vs 68.1%, P = 0.06) and NRM (6% vs 7%; P = 0.98). The 3-year RI was higher in the CD34+ group (42.6% vs 24.8%; P = 0.04; Figure 1 ). These results were not confirmed when adjusting for other factors by multivariate analysis.
By multivariate analysis, there was no statistically significant difference between the CD34+ and non-selected groups in terms of OS (hazard ratio (HR): 0.98; 95% CI 0.40-2.39; P = 0.96), PFS (HR: 1.55, 95% CI 0.83-2.88: P = 0.17) and RI (HR: 1.70; 95% CI 0.85-3.38; P = 0.13). For other factors, OS was lower in the presence of heart involvement at SSc diagnosis (HR: 6.69; 95% CI 2.43-18.45; P = 0.0002) and of modified Rodnan's skin score 424 at mobilization (HR: 2.62; 95% CI 1.07-6.44; P = 0.04). The RI was higher in the presence of gastrointestinal involvement at SSc diagnosis (HR: 2.31; 95% CI 1.14-4.67; P = 0.02). These results are supported by previous studies where we 13, 14 and others 15 had shown that heart involvement in SSc negatively affects patient outcome.
The main purpose of this study was to determine whether positive CD34+ selection influenced clinical outcomes of AHSCT in SSc patients. Graft selection may affect lymphocyte ontogeny and delay immune reconstitution after transplant, as shown in previous studies. 16, 17 Indeed, in allogeneic transplants, CD34+ selection delayed the CD4 T-lymphocyte reconstitution process, but the difference disappeared 8 months after transplantation, when compared with non-selected patients under similar conditions. 16 In addition, when comparing haploidentical hematopoietic stem cell transplant outcomes after ex vivo CD34+ selection or in vivo purging (alemtuzumab), the incidence of infections was similar, 17 indicating that both depletion methods are equally immunosuppressive.
Viral infections have been reported in AD patients after T-celldepleted AHSCT. 18, 19 However, although only one study 20 specifically addressed the issue, there is a general lack of evidence for CD34+ selection in AD. 11, 12, 21, 22 The exception is a lupus study 19 which provides weak support, suggesting that effects may be disease specific. In our study, graft selection had no impact on the clinical results, especially on the neutrophil engraftment and infections were reported in 30% (19/63) of the CD34+ selected vs 34% (19/56 ) of the non-selected group (P = 0.66).
The potential risk of re-injecting pathological T-cells with nonselected grafts may be outweighed by high cost, reduced numbers of transplanted cells and increased immunosuppression in patients receiving CD34+ grafts. 18, 20, 23, 24 In the present study, CD34+ selection did not improve disease control after AHSCT. Unexpectedly, we detected a trend toward better outcomes in non-selected patients, with lower relapse rates and higher PFS. Although these findings may appear counter intuitive, it is possible that, besides removing autoreactive T-cells, the selection process may also eliminate regulatory T-cells and other protective cellular effectors. 25 Recent publications on post-transplantation immune monitoring in AD have shown that it is more important to promote a balance between tolerance and autoreactivity than to completely ablate the original immune system. 12, 26, 27 This is achieved via an increase in the number and function of regulatory cells, with thymic reactivation, emergence of a polyclonal TCR repertoire and normalization of epigenetic abnormalities among other immunological effects. 27, 28 Therefore, the potential reinfusion of autoreactive T-cells within the non-selected graft may not be clinically relevant in SSc, as other mechanisms may be operating for reset of the immunological balance and disease control after AHSCT in AD. Further studies to explore details of CD34+ selection, such as the degree of T-cell depletion and post-transplant lymphocyte reconstitution, are still required.
Finally, we cannot ignore that the retrospective nature of the study may have affected the results and limited its conclusions. Nevertheless, we believe that our findings do contribute to reduce costs, decrease the operational complexity and may increase safety of AHSCT for SSc.
CONCLUSIONS
This ADWP EBMT retrospective study demonstrates that ex vivo CD34+ selection of the graft does not add benefit to the OS, PFS and NRM in SSc patients after AHSCT. It also shows that SSc heart Abbreviations: NRM = non-relapse mortality; OS = overall survival; RI = relapse incidence.
a
Transplants not including ATG in the conditioning regimen were excluded from the analysis (n = 11). Abbreviations: AHSCT = autologous hematopoietic stem cell transplantation; ATG = antithymocyte globulin; Cyclo = cyclophosphamide; IQR = interquartile range; mRSS = modified Rodnan skin score; SSc = systemic sclerosis. P-values in bold correspond to significant results (Po0.05).
a P-value is not relevant due to the low numbers in some groups.
involvement at baseline decreases OS and that gastrointestinal involvement contributes to disease progression after AHSCT. Further prospective randomized trials, under controlled and more homogeneous conditions, are warranted to confirm these findings. 
